Hyperforin

Research use only, not for human use.

Hyperforin is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin modulates Ca2+ levels by activating Ca2+-conducting non-selective canonical TRPC6 channels and triggers adipose tissue thermogenesis via the Dlat-AMPK signaling axis to suppress obesity. Hyperforin also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin modulates γδ T cells to secret IL-17α, improves Imiquimod -induced psoriasis-like mice model.

Hyperforin acts as an angiogenesis inhibitor, it as a possible antidepressant component of hypericum extracts.

Hyperforin has a multi-directional mechanism of action. It blocks conductance of ligand-gated (GABA, NMDA, and AMPA receptors) and voltage-gated channels (Ca2+, K+, and Na+).Hyperforin (0.1, 1, 10 μM; 2 h) reduces the expression and secretion of IL-17A in γδ T cell in vitro cultured murine splenic γδ T cells.Hyperforin (0.1, 1, 10 μM; 2 h) suppresses phosphorylation of MAPK and STAT3 pathways in TNF-α stimulated HaCaT cells.Hyperforin (IC50=3.7 μmol/L) inhibits the microvascular tube formation and proliferation of HDMEC in a dose-dependent manner without toxic effects.Western Blot Analysis Cell Line:HaCaT cells Concentration:0.1, 1, 10 μM; with or without 10, 20 ng/mL TNF-αIncubation Time:2 hours Result:Reduced the expressions of p-p38, p-ERK, p-JNK, and p-STAT3, especially at the dosage of 10 μM.

Hyperforin (5 mg/kg; i.p.; once daily for 7 d) ameliorates Imiquimod-induced psoriatic skin lesion in mice, as well as inhibiting inflammatory cell infiltration and inflammatory cytokines release.Animal Model:IMQ-induced psoriasis-like mice model Dosage:5 mg/kg Administration:Intraperitoneal injection; once daily for 7 days Result:Significantly ameliorated skin lesion throughout the treatment period, demonstrated by the reduced severity score of skin inflammation.Suppressed infiltration of CD3+ T cells and downregulated expression of Il1, Il6, Il23, Il17a, Il22, antimicrobial peptides (AMPs) in the skin lesion.

———

Endocrinology/Hormones

5-HT Receptor

COX-1;5-HT

———

———

11079-53-1

536.79

C35H52O4

>98% (HPLC)

———

C(C(C)C)(=O)[C@@]12[C@@](CCC=C(C)C)(C)[C@@H](CC=C(C)C)C[C@@](CC=C(C)C)(C1=O)C(=O)C(CC=C(C)C)=C2O

——

(-20℃)

With Ice Pack

≥ 2 years